MKMarvin A. Konstam

Marvin A. Konstam

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marvin A. Konstam has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Alise Reicin

    From the Division of Cardiology, New England Medical Center, Boston, Mass (M.A.K.); the Nephrology Division, University of Maryland Hospital, Baltimore (M.R.W.); and Merck Research Laboratory, Merck, Whitehouse Station, NJ (A.R., D.S., R.S.S., E.B., B.J.G.).

    1 shared publication
  • Barry J. Gertz

    From the Division of Cardiology, New England Medical Center, Boston, Mass (M.A.K.); the Nephrology Division, University of Maryland Hospital, Baltimore (M.R.W.); and Merck Research Laboratory, Merck, Whitehouse Station, NJ (A.R., D.S., R.S.S., E.B., B.J.G.).

    1 shared publication
  • Deborah Shapiro

    From the Division of Cardiology, New England Medical Center, Boston, Mass (M.A.K.); the Nephrology Division, University of Maryland Hospital, Baltimore (M.R.W.); and Merck Research Laboratory, Merck, Whitehouse Station, NJ (A.R., D.S., R.S.S., E.B., B.J.G.).

    1 shared publication
  • Douglas L. Mann

    Center for Cardiovascular Research, Cardiovascular Division Washington University School of Medicine St. Louis Missouri USA

    1 shared publication
  • Eliav Barr

    From the Division of Cardiology, New England Medical Center, Boston, Mass (M.A.K.); the Nephrology Division, University of Maryland Hospital, Baltimore (M.R.W.); and Merck Research Laboratory, Merck, Whitehouse Station, NJ (A.R., D.S., R.S.S., E.B., B.J.G.).

    1 shared publication
  • Matthew R Weir

    1 shared publication

Latest Publications

  • Open Access

    Current perspective on the cardiovascular effects of coxibs.

    by Marvin A Konstam, Matthew R Weir

    Aspirin and nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for their anti-inflammatory and analgesic effects. In addition, aspirin is documented to reduce cardiovascular events in selected populations, presumably because of inhibition of platelet aggregation. Yet these drugs are not without toxicity, particularly adverse effects on the gastric mucosa. The gastrointestinal toxicity of nonselective NSAIDs and aspirin derives from the inhibition of the cyclooxygenase (COX) enzyme, COX-1, which synthesizes gastroprotective prostaglandins, while the anti-inflammatory and pain-relieving effects are largely derived from inhibition of COX-2-derived prostaglandins. Available data indicate that the harmful gastric effects of nonselective NSAIDs are reduced by substitution of agents that only inhibit the COX-2 protein. The COX-2-selective inhibitors, however, have also been shown to inhibit the production of vascular prostacyclin, which has vasodilatory effects and inhibits platelet aggregation; unlike nonselective NSAIDs, they do not inhibit the production of thromboxane, an eicosanoid that promotes platelet aggregation. Whether these effects could potentially contribute to a prothrombotic environment is the subject of current, intensive debate. In the Vioxx Gastrointestinal Outcomes Research (VIGOR) trial, there was a higher incidence of cardiovascular thrombotic events in the rofecoxib- vs the naproxen-treated group: 1.67 vs 0.70 per 100 patient years. However, in a pooled analysis of rofecoxib studies, the risk of sustaining a thrombotic cardiovascular event was similar when comparing patients receiving rofecoxib with those receiving placebo, or when comparing patients receiving rofecoxib with those receiving nonnaproxen nonselective NSAIDs. These findings are likely to result, at least in part, from the antiplatelet action of naproxen, which has been shown to be potent and sustained during a typical dosing regimen (500 mg twice daily in VIGOR). In contrast, the other NSAID comparators effect weaker and/or nonsustained antiplatelet action. In the Celecoxib Long-term Arthritis Safety Study (CLASS) trial, there was no difference between celecoxib and the nonselective NSAIDs explored (which did not include naproxen) in cardiovascular event rates. Unlike those in VIGOR, patients in the CLASS trial were allowed to take low-dose aspirin. Thus, despite concerns raised by results of VIGOR, other existing data, including those pooled from existing placebo-controlled trials, do not support a clinically relevant prothrombotic effect of the COX-2 inhibitors. Additional placebo-controlled data, from patients at both high and low risk for cardiovascular events, are warranted to clarify the cardiovascular effects of this class of agents.


  • Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib

    by Marvin A. Konstam, Matthew R. Weir, Alise Reicin, Deborah Shapiro, Rhoda S. Sperling, Eliav Barr, Barry J. Gertz

    Background In comparing aspirin, nonselective nonsteroidal antiinflammatory agents (NSAIDs), and cyclooxygenase (COX)-2 inhibitors, variation in platelet inhibitory effects exists that may be associated with differential risks of cardiovascular (CV) thrombotic events. Among the randomized, controlled trials with the COX-2 inhibitor rofecoxib, one study demonstrated a significant difference between rofecoxib and its NSAID comparator (naproxen) in the risk of CV thrombotic events. A combined analysis of individual patient data was undertaken to determine whether there was an excess of CV thrombotic events in patients treated with rofecoxib compared with those treated with placebo or nonselective NSAIDs. Methods and Results CV thrombotic events were assessed across 23 phase IIb to V rofecoxib studies. Comparisons were made between patients taking rofecoxib and those taking either placebo, naproxen (an NSAID with near-complete inhibition of platelet function throughout its dosing interval), or another nonselective NSAIDs used in the development program (diclofenac, ibuprofen, and nabumetone). The major outcome measure was the combined end point used by the Antiplatelet Trialists’ Collaboration, which includes CV, hemorrhagic, and unknown deaths; nonfatal myocardial infarctions; and nonfatal strokes. More than 28 000 patients, representing >14 000 patient-years at risk, were analyzed. The relative risk for an end point was 0.84 (95% CI: 0.51, 1.38) when comparing rofecoxib with placebo; 0.79 (95% CI: 0.40, 1.55) when comparing rofecoxib with non-naproxen NSAIDs; and 1.69 (95% CI: 1.07, 2.69) when comparing rofecoxib with naproxen. Conclusions This analysis provides no evidence for an excess of CV events for rofecoxib relative to either placebo or the non-naproxen NSAIDs that were studied. Differences observed between rofecoxib and naproxen are likely the result of the antiplatelet effects of the latter agent.


  • Progress in Heart Failure Management?

    by Marvin A. Konstam